Status:
RECRUITING
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Eligibility Criteria
Inclusion
- Fully understand the study and voluntarily sign the informed consent form;
- Male or female 18\~75 years of age;
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
- Life expectancy ≥ 3 months;
- Histologically or cytologically confirmed Small Cell Lung Cancer.
Exclusion
- Participants were deemed unsuitable for participating in the study by the investigator for any reason.
Key Trial Info
Start Date :
December 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT07189455
Start Date
December 12 2025
End Date
December 1 2028
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China, 200030